Essential Health Group President Angela Hwang, Biosimilars President Richard Blackburn and US Biosimilars General Manager John Kennedy discuss the early challenges Pfizer has faced with Inflectra and optimism for the US biosimilars market over the long term.
Pfizer Inc. is in the biosimilar market for the long game, despite the commercial challenges it has faced with its first biosimilar to launch in the US – Inflectra (infliximab-dyyb). That was the message the company's Essential Health leadership set out during a briefing on the company's biosimilar strategy at Pfizer's New York headquarters April 10.
"The market for biosimilars is alive and it's real and it's here to stay," Essential Health Group President Angela Hwang...
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?
GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut
